Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevo nanomaterial de óxido de hierro para diagnóstico y tratamiento

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOGR20150717004
Publicado:
18/08/2015
Caducidad:
17/08/2016
Resumen:
Un grupo de investigación griego ha desarrollado un nuevo nanomaterial que se utiliza como agente de contraste en diagnóstico médico por IRM (imagen por resonancia magnética). Este nanomaterial ofrece características superiores, como mejor contraste de imagen, alta estabilidad y dispersabilidad, baja toxicidad, bajos costes de producción y aplicación en administración dirigida de medicamentos como agente para diagnóstico guiado por imagen y tratamiento, o hipertermia magnética. Se buscan socios de la industria farmacéutica con el fin de establecer acuerdos de investigación y licencia.

Details

Tittle:
Novel iron oxide nanomaterial for diagnosis -Y- therapy
Summary:
A Greek research group has developed a novel nanomaterial, to be used as contrast agent for MRI medical diagnosis. The nanomaterial offers superior characteristics, e.g. enhanced image contrast, high stability and dispersibility , low toxicity, low cost of production, while it is applicable in targeted drug delivery as an agent for image-guided diagnosis and therapy. The research group seeks partners from the pharmaceutical industry for research cooperation or license agreement.
Description:
Magnetic Resonance Imaging (MRI) is one of the most powerful medical diagnosis techniques. It is a non-invasive technique for 3D high-resolution examinations of the healthy or diseased tissues, internal organs and cells of the human body. The diagnostic power of MRI is highly dependent on the properties of the contrast agent, which is injected in the human body and "highlights" the areas under observation.

The proposed nanomaterial based on magnetic iron-oxide nanoparticles is promising as contrast agent for MRI, because of the improved contrast enhancement of the image that can provide compared to MRI agents currently used, while it also performs improved magnetic properties. Its advantageous use can be assisted by MRI, as it can provide real-time observation of drug accumulation in a selected tissue targeted drug delivery

Preliminary experiments of iron-oxide nanostructures incubated with living cells, indicated low levels of toxicity, cell-cell interactions suggest nice tolerance and high viability giving further support towards the potential use of the proposed technology in MRI-based technologies.

The nanomaterial targets mainly the pharmaceutical industry and can be used not only as a diagnostic agent for MRI but also as a therapeutic agent for therapeutic aims., Therefore, it could also be used in magnetically driven hyperthermia and targeted drug delivery. In this way the same agent would carry the drug to the target, and through MRI it can assist in having a real-time evaluation of drug absorbency and efficiency.

The Greek research group seeks partners mainly from the pharmaceutical industry for research cooperation in the fields of magnetically driven hyperthermia and targeted drug delivery or for license agreement.

The research group is part of a large physics -Y- materials research centre in Greece that performs high quality fundamental and applied scientific research focusing on two main research directions, i)laser science -Y- photonics and ii) materials -Y- devices science -Y- technology.
Advantages and Innovations:
· Performs stable magnetic properties. The novel nonmaterial has been developed with a novel synthesis procedure based on a high temperature chemistry pathway, which offers high stability and uniformity of the end product. The material consists of pure iron-oxide, free from impurities and exhibits homogeneous and narrow size distribution, 10 times better than common MRI contrast agents.
· High contrast efficiency. Commercial iron-oxide nanoparticles demonstrate low magnetization, which limits the contrast and resolution of the image in MRI. The new product is characterized by a high saturation magnetization, which means high contrast efficiency and resolution of the image.
· Low toxicity. Preliminary experiments in living cells, indicated low levels of toxicity, cell-cell interactions, and high viability, supporting the potential use of the proposed technology in MRI applications.
· Cost efficiency. It can be produced easily and at significantly low cost as it needs only one-step synthesis. It also uses cheaper reactants than gadolinium based contrast agents and the commercial product Endorem® (iron-oxide based).
· Superior contrast agent characteristics. It is water dispersible and stable into aqueous solution without further functionalization with the advantage of lower hydrodynamic volume (80 nm) compared to those of Endorem (150-180 nm).
· Versatility. It can be used not only as a diagnostic but also as a therapeutic agent.
Stage of Development:
Under development/lab tested
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
Patents granted in Greece.

Partner sought

Type and Role of Partner Sought:
The Greek research group seeks partners from the pharmaceutical industry for research cooperation in the fields of magnetically driven hyperthermia and targeted drug delivery or for license agreement.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English

Keywords

Technology Keywords:
02007024 Nanomaterials